ABSTRACT
Wilms tumor, the most common kidney cancer in pediatrics, arises from embryonic renal progenitors. Although many patients are cured with multimodal therapy, outcomes remain poor for those with high-risk features. Recent sequencing efforts have provided few biological or clinically actionable insights. Here, we performed DNA and RNA sequencing on 94 Wilms tumors to understand how Wilms tumor mutations transform the transcriptome to arrest differentiation and drive proliferation. We show that most Wilms tumor mutations fall into four classes, each with unique transcriptional signatures: microRNA processing, MYCN activation, chromatin remodeling, and kidney development. In particular, the microRNA processing enzyme DROSHA is one of the most commonly mutated genes in Wilms tumor. We show that DROSHA mutations impair pri-microRNA cleavage, de-repress microRNA target genes, halt differentiation, and overexpress cyclin D2 (CCND2). Several mutational classes converge to drive CCND2 overexpression, which could render them susceptible to cell-cycle inhibitors.
Significance Through integrated DNA and RNA sequencing analyses, we demonstrate novel genotype-transcriptome associations in Wilms tumors that converge to drive CCND2 overexpression. Thus, although Wilms tumor mutations are not currently targetable, their effects on the transcriptome may be.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funding from the National Cancer Institute (P50CA196516 to J.F.A.; K08CA207849 to K.S.C.; and R21CA259771 and P30CA142543 to L.X.), Cancer Prevention and Research Institute of Texas (RR180071 to K.S.C.; RP180805 to L.X.), and the Rally Foundation (to L.X.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of UT Southwestern Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: This work was supported by funding from the National Cancer Institute (P50CA196516 to J.F.A.; K08CA207849 to K.S.C.; and R21CA259771 and P30CA142543 to L.X.), Cancer Prevention and Research Institute of Texas (RR180071 to K.S.C.; RP180805 to L.X.), and the Rally Foundation (to L.X.).
The authors declare no potential conflicts of interest.
Data Availability
All data produced in the present study will be uploaded to dbGAP upon publication.